The recipients of this year's Richard C. Talamo Distinguished Clinical Achievement Award, presented at the 2014 North American Cystic Fibrosis Conference, represent a successful collaboration between researchers and clinicians to bring about a significant advance in CF care and treatment. The award is one of the highest honors given by the Cystic Fibrosis Foundation.
Site Search
William Skach, MD, Chief Scientific Officer, will retire from the CF Foundation this summer.
As part of its Building Trust Video series, the Better Business Bureau's (BBB) Wise Giving Alliance is featuring an interview with Preston W. Campbell, III, M.D., president and CEO of the Cystic Fibrosis Foundation.
The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
In the largest forum of its kind, more than 4,000 doctors, scientists and caregivers from around the world are meeting today in Atlanta for the 28th annual North American Cystic Fibrosis Conference (NACFC).
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.
Legislation introduced today will help more people with cystic fibrosis, and other rare diseases, participate in clinical trials without fear of losing important benefits or health coverage. The bill is sponsored by a bipartisan group of senators and legislators.